SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, taking place from Sept. 29 to Oct. 2. The companies will present the latest research findings on BYETTA® (exenatide) injection and exenatide once weekly. The EASD annual meeting, which brings together more than 14,000 delegates, is the most important platform in Europe for professional exchange in the diabetes field.
